Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integral DiagnosticsITGDF 72 EV-to-EBITDA is 11.83 as of Jul. 27, 2026, which is 8% below its 10-year median of 12.84. GuruFocus rates ITGDF with a GF Score™ of 72/100 and a GF Value™ of $1.17 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Integral Diagnostics ranks better than 62.39% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Integral Diagnostics's enterprise value is $933.4 Mil.
Integral Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $78.9 Mil. Therefore, Integral Diagnostics's EV-to-EBITDA for today is 11.83.
The historical rank and industry rank for Integral Diagnostics's EV-to-EBITDA or its related term are showing as below:
ITGDF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.03 Med: 12.84 Max: 156.42
Current: 11.15
During the past 10 years, the highest EV-to-EBITDA of Integral Diagnostics was 156.42. The lowest was 7.03. And the median was 12.84.
ITGDF's EV-to-EBITDA is ranked better than 62.39% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.4
vs ITGDF: 11.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Integral Diagnostics (OTCPK:ITGDF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Integral Diagnostics's PE Ratio (TTM) for today is calculated as:
Integral Diagnostics's share price for today is $2.6125.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Integral Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.027.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Integral Diagnostics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integral Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's EV-to-EBITDA falls into.
Integral Diagnostics's current Enterprise Value is $933.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Integral Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $78.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ITGDF) has a EV-to-EBITDA of 11.83 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Integral Diagnostics. This is near median its historical median of 12.84. Over the past decade, Integral Diagnostics' EV-to-EBITDA has ranged from 7.03 to 156.42. According to the industry distribution chart, Integral Diagnostics ranks #44 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 37.6%.
Is Integral Diagnostics' EV-to-EBITDA too high?
Integral Diagnostics' current EV-to-EBITDA of 11.83 is near median its 10-year median of 12.84. Over the past 10 years, this metric has ranged from a low of 7.03 to a high of 156.42. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.40. Integral Diagnostics' value of 11.83 is 17.8% below this industry median. Based on the distribution chart, Integral Diagnostics ranks #44 out of 117 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Integral Diagnostics has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #44 out of 117 companies for EV-to-EBITDA. This puts Integral Diagnostics in the upper half of its industry. The industry median EV-to-EBITDA is 14.40. Integral Diagnostics' value of 11.83 is 17.8% below this benchmark. Historically, Integral Diagnostics' own EV-to-EBITDA has ranged from 7.03 to 156.42 over the past decade. While the company's 10-year median is 12.84 vs. the industry median of 14.40, Integral Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.40, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current EV-to-EBITDA of 11.83 is 17.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Integral Diagnostics. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current EV-to-EBITDA is 11.83, which is near median its own 10-year median of 12.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ITGDF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.17, compared to a current price of $2.61 — trading 123.3% above its estimated fair value. The current EV-to-EBITDA is 11.83, which is near median its 10-year median of 12.84 and 17.8% below the Medical Diagnostics & Research industry median of 14.40. Integral Diagnostics' overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Integral Diagnostics (ITGDF), the current EV-to-EBITDA is 11.83 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ITGDF) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be overvalued.
The current stock price of $2.61 is trading 123.3% above its estimated GF Value™ of $1.17.
GuruFocus considers Integral Diagnostics to be Significantly Overvalued.
Key valuation signals for ITGDF:
EV-to-EBITDA: 11.83 (near median its 10-year median of 12.84)
GF Value™: $1.17 vs. price of $2.61 (123.3% above fair value)
Industry Position: 17.8% below the Medical Diagnostics & Research median (#44 of 117)
No single metric tells the full story. See the ITGDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
72GF Score
Get the complete analysis for ITGDF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITGDF has been successfully added to your 
